New Atopic Dermatitis Clinical Trial Protocol R668-AD-0914 – Regeneron Pharmaceuticals, Inc.

September 8, 2011

This study is currently being conducted at ten centers in the United States. If patients are qualified for the study, they are treated with study drug once a week for four weeks, and then followed by the site staff for an additional two months. There are a total of 15 study visits over twelve weeks, for which patients can be compensated for their time and travel.

Principal Investigator:

Lisa Beck, MD – University of Rochester, Department of Dermatology

Clinical Trials Listing:

For more information, please contact:

Deidre Stonestreet – Sr. Project Manager – i3, an Inventiv Healthcare Company
Telephone: 301-253-1535

Please click here to return to the Clinical Trials main page